Evolution of COVID-19 mortality over time: results from the Swiss hospital surveillance system (CH-SUR).


Journal

Swiss medical weekly
ISSN: 1424-3997
Titre abrégé: Swiss Med Wkly
Pays: Switzerland
ID NLM: 100970884

Informations de publication

Date de publication:
22 11 2021
Historique:
entrez: 29 11 2021
pubmed: 30 11 2021
medline: 15 12 2021
Statut: epublish

Résumé

When the periods of time during and after the first wave of the ongoing SARS-CoV-2/COVID-19 pandemic in Europe are compared, the associated COVID-19 mortality seems to have decreased substantially. Various factors could explain this trend, including changes in demographic characteristics of infected persons and the improvement of case management. To date, no study has been performed to investigate the evolution of COVID-19 in-hospital mortality in Switzerland, while also accounting for risk factors. We investigated the trends in COVID-19-related mortality (in-hospital and in-intermediate/intensive-care) over time in Switzerland, from February 2020 to June 2021, comparing in particular the first and the second wave. We used data from the COVID-19 Hospital-based Surveillance (CH-SUR) database. We performed survival analyses adjusting for well-known risk factors of COVID-19 mortality (age, sex and comorbidities) and accounting for competing risk. Our analysis included 16,984 patients recorded in CH-SUR, with 2201 reported deaths due to COVID-19 (13.0%). We found that overall in-hospital mortality was lower during the second wave of COVID-19 than in the first wave (hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.63- 0.78; p <0.001), a decrease apparently not explained by changes in demographic characteristics of patients. In contrast, mortality in intermediate and intensive care significantly increased in the second wave compared with the first wave (HR 1.25, 95% CI 1.05-1.49; p = 0.029), with significant changes in the course of hospitalisation between the first and the second wave. We found that, in Switzerland, COVID-19 mortality decreased among hospitalised persons, whereas it increased among patients admitted to intermediate or intensive care, when comparing the second wave to the first wave. We put our findings in perspective with changes over time in case management, treatment strategy, hospital burden and non-pharmaceutical interventions. Further analyses of the potential effect of virus variants and of vaccination on mortality would be crucial to have a complete overview of COVID-19 mortality trends throughout the different phases of the pandemic.

Sections du résumé

BACKGROUND
When the periods of time during and after the first wave of the ongoing SARS-CoV-2/COVID-19 pandemic in Europe are compared, the associated COVID-19 mortality seems to have decreased substantially. Various factors could explain this trend, including changes in demographic characteristics of infected persons and the improvement of case management. To date, no study has been performed to investigate the evolution of COVID-19 in-hospital mortality in Switzerland, while also accounting for risk factors.
METHODS
We investigated the trends in COVID-19-related mortality (in-hospital and in-intermediate/intensive-care) over time in Switzerland, from February 2020 to June 2021, comparing in particular the first and the second wave. We used data from the COVID-19 Hospital-based Surveillance (CH-SUR) database. We performed survival analyses adjusting for well-known risk factors of COVID-19 mortality (age, sex and comorbidities) and accounting for competing risk.
RESULTS
Our analysis included 16,984 patients recorded in CH-SUR, with 2201 reported deaths due to COVID-19 (13.0%). We found that overall in-hospital mortality was lower during the second wave of COVID-19 than in the first wave (hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.63- 0.78; p <0.001), a decrease apparently not explained by changes in demographic characteristics of patients. In contrast, mortality in intermediate and intensive care significantly increased in the second wave compared with the first wave (HR 1.25, 95% CI 1.05-1.49; p = 0.029), with significant changes in the course of hospitalisation between the first and the second wave.
CONCLUSION
We found that, in Switzerland, COVID-19 mortality decreased among hospitalised persons, whereas it increased among patients admitted to intermediate or intensive care, when comparing the second wave to the first wave. We put our findings in perspective with changes over time in case management, treatment strategy, hospital burden and non-pharmaceutical interventions. Further analyses of the potential effect of virus variants and of vaccination on mortality would be crucial to have a complete overview of COVID-19 mortality trends throughout the different phases of the pandemic.

Identifiants

pubmed: 34843180
doi: 10.4414/smw.2021.w30105
pii: Swiss Med Wkly. 2021;151:w30105
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

w30105

Auteurs

Maroussia Roelens (M)

Institute of Global Health, Faculty of Medicine, University of Geneva, Switzerland.

Alexis Martin (A)

Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Switzerland.

Brian Friker (B)

Veterinary Public Health Institute, University of Bern, Switzerland.

Filipe Maximiano Sousa (FM)

Veterinary Public Health Institute, University of Bern, Switzerland.

Amaury Thiabaud (A)

Institute of Global Health, Faculty of Medicine, University of Geneva, Switzerland.

Beatriz Vidondo (B)

Veterinary Public Health Institute, University of Bern, Switzerland.

Valentin Buchter (V)

Swiss Federal Office of Public Health, Bern, Switzerland.

Céline Gardiol (C)

Swiss Federal Office of Public Health, Bern, Switzerland.

Jasmin Vonlanthen (J)

Swiss Federal Office of Public Health, Bern, Switzerland.

Carlo Balmelli (C)

Infection Control Programme, EOC Hospitals, Ticino, Switzerland.

Manuel Battegay (M)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland.

Christoph Berger (C)

Division of Infectious Diseases, and Children's Research Centre, University Children's Hospital Zurich, Switzerland.

Michael Buettcher (M)

Paediatric Infectious Diseases, Department of Paediatrics, Children's Hospital, Cantonal Hospital Lucerne, Switzerland.

Alexia Cusini (A)

Department of Infectious Diseases, Cantonal Hospital Graubuenden, Chur, Switzerland.

Domenica Flury (D)

Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, Switzerland.

Ulrich Heininger (U)

Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel, Switzerland.

Anita Niederer-Loher (A)

Children's Hospital of Eastern Switzerland, St Gallen, Switzerland.

Thomas Riedel (T)

Department of Paediatrics, Cantonal Hospital Graubuenden, Chur, Switzerland.

Peter W Schreiber (PW)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Switzerland.

Rami Sommerstein (R)

Department of Infectious Diseases, Bern University Hospital (Inselspital), Bern, Switzerland.
Infectious Diseases and Hospital Hygiene Clinic St Anna, Department of Health Sciences and Medicine, University of Lucerne, Switzerland.

Nicolas Troillet (N)

Service of Infectious Diseases, Central Institute, Valais Hospitals, Sion, Switzerland.

Sarah Tschudin-Sutter (S)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Switzerland.

Pauline Vetter (P)

Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland.

Sara Bernhard-Stirnemann (S)

Children's Hospital Aarau, Switzerland.

Natascia Corti (N)

Unit of General Internal Medicine, Hirslanden Clinic, Zurich, Switzerland.

Roman Gaudenz (R)

Internal Medicine and Infectiology, Cantonal Hospital Nidwalden, Stans, Switzerland.

Jonas Marschall (J)

Department of Infectious Diseases, Bern University Hospital (Inselspital), Bern, Switzerland.

Yvonne Nussbaumer-Ochsner (Y)

Clinic for Internal Medicine, Cantonal Hospital, Hospitals Schaffhausen, Switzerland.

Laurence Senn (L)

Service of Preventive Medicine, Lausanne University Hospital, CHUV, Lausanne, Switzerland.

Danielle Vuichard-Gysin (D)

Division of Infectious Diseases and Hospital Hygiene, Thurgau Hospital Group Münsterlingen and Frauenfeld, Switzerland.

Petra Zimmermann (P)

Faculty of Science and Medicine, University of Fribourg, Switzerland.
Department of Paediatrics, Fribourg Hospital HFR, Fribourg, Switzerland.

Franziska Zucol (F)

Paediatric Infectious Diseases, Department of Paediatrics, Cantonal Hospital Winterthur, Switzerland.

Anne Iten (A)

Service of Prevention and Infection Control, Directorate of Medicine and Quality, University Hospital Geneva, HUG, Geneva, Switzerland.

Olivia Keiser (O)

Institute of Global Health, Faculty of Medicine, University of Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH